



A long-acting monoclonal antibody to **help protect infants against RSV-LRTI**

Learn about compelling data for infant RSV immunization to support your immunization efforts for the 2025–2026 RSV season

Please join us for a complimentary 45-minute webinar, which includes Q&A with our expert to review:

- The risks of RSV in infants, including those born before the RSV season
- Compelling, novel real-world evidence describing the safety and impact of Beyfortus®
- Guidance on AAP, ACIP, and CDC recommendations
- Advice on dosing timing and co-administration with vaccines, hospital vs clinic workflows, and supply/logistics

There are 2 LIVE 45-minute events available for your convenience.

Date	Eastern	Central	Mountain	Pacific
8/13/2025	12:00 PM	11:00 AM	10:00 AM	9:00 AM
8/13/2025	3:00 PM	2:00 PM	1:00 PM	12:00 PM



Target Audience

Physicians, pharmacists, practice managers, nurse practitioners, physician assistants, registered nurses, medical assistants

Preregistration is required to secure your spot.

8/13/2025

12 PM EST: Register

3 PM EST: Register

If you have trouble registering, please contact Sanofi at **1-888-502-6180**. Payments and other certain types of transfers of value by pharmaceutical manufacturers to covered recipients may need to be reported according to the federal Sunshine Act, as well as state laws.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder, or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full **Prescribing Information**.

Beyfortus®
(nirsevimab-alip) | 50 mg
100 mg
Injection

sanofi